ESPERTI PHARMACEUTICALS Trademark

Trademark Overview


On Monday, June 14, 2021, a trademark application was filed for ESPERTI PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the ESPERTI PHARMACEUTICALS trademark a serial number of 90772225. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, May 16, 2023. This trademark is owned by Esperti Pharmaceuticals, LLC. The ESPERTI PHARMACEUTICALS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Consulting services in the field of pharmaceuticals and biotechnology research and development; consulting services for others in the field of design, planning, support and implementation of programs for scientific research of pharmaceuticals, laboratory testing of pharmaceuticals, diagnostics for pharmaceuticals, clinical trials of pharmaceuticals, testing, modeling and simulation of pharmaceuticals, and due diligence and audit of such programs; quality management services, namely quality evaluation and analysis, quality assurance, and quality control in the field of pharmaceutical drug manufacturing and contract manufacturing; consulting pertaining to pharmacokinetics and biostatistics; conducting scientific feasibility studies
esperti pharmaceuticals

General Information


Serial Number90772225
Word MarkESPERTI PHARMACEUTICALS
Filing DateMonday, June 14, 2021
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, May 16, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Translation of Words in MarkThe English translation of ESPERTI in the mark is EXPERTS.
Disclaimer with Predetermined Text"PHARMACEUTICALS"
Goods and ServicesConsulting services in the field of pharmaceuticals and biotechnology research and development; consulting services for others in the field of design, planning, support and implementation of programs for scientific research of pharmaceuticals, laboratory testing of pharmaceuticals, diagnostics for pharmaceuticals, clinical trials of pharmaceuticals, testing, modeling and simulation of pharmaceuticals, and due diligence and audit of such programs; quality management services, namely quality evaluation and analysis, quality assurance, and quality control in the field of pharmaceutical drug manufacturing and contract manufacturing; consulting pertaining to pharmacokinetics and biostatistics; conducting scientific feasibility studies

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 1, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEsperti Pharmaceuticals, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressBallwin, MO 63021

Trademark Events


Event DateEvent Description
Tuesday, May 16, 2023ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Tuesday, May 16, 2023ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Tuesday, May 16, 2023ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, October 11, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 11, 2022NON-FINAL ACTION E-MAILED
Tuesday, October 11, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 6, 2022ASSIGNED TO EXAMINER
Thursday, September 1, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, August 31, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 31, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, March 5, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, March 5, 2022NON-FINAL ACTION E-MAILED
Saturday, March 5, 2022NON-FINAL ACTION WRITTEN
Friday, March 4, 2022ASSIGNED TO EXAMINER
Wednesday, September 1, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 17, 2021NEW APPLICATION ENTERED